Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07335406Recruiting

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Role: lead

NCT07352098Not ApplicableNot Yet Recruiting

7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori

Role: lead

NCT07333001Completed

Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication

Role: lead

NCT07285096Recruiting

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Role: lead

NCT07167511Completed

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Role: lead

All 5 trials loaded